Bicycle Therapeutics PLC (BCYC)

Name: Bicycle Therapeutics PLC (BCYC) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name BICYCLE THERAPEUTICS PLC · CIK 0001761612 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Bicycle Therapeutics PLC reported revenue of $72.59M. Revenue grew 105.8% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $61.20M.

Key ratios (year ended 2025-12-31)

-340.4%

Operating margin

-301.7%

Net margin

-35.9%

Return on year-end equity

105.8%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4/A (ownership change) · 2026-10-07

Headquarters locality: Cambridge · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Revenue	$61.20M	$72.59M	$35.27M	$26.98M	$14.46M	$11.70M	$10.39M	$13.80M	$7.14M	$2.06M
R&D Expense	$200.26M	$240.28M	$172.97M	$156.50M	$81.61M	$44.88M	$33.15M	$25.54M	$20.76M	$11.87M
Operating Income	-$210.30M	-$247.06M	-$209.87M	-$189.95M	-$116.65M	-$65.62M	-$51.96M	-$26.30M	-$21.75M	-$16.21M
Depreciation & Amortization	$5.29M	$6.42M	$7.17M	$6.55M	$3.69M	$1.41M	$1.28M	$960.0K	$712.0K	$332.0K
EBITDA	-$205.01M	-$240.64M	-$202.70M	-$183.40M	-$112.96M	-$64.21M	-$50.68M	-$25.34M	-$21.03M	-$15.88M
Net Income	-$190.41M	-$218.96M	-$169.03M	-$180.66M	-$112.72M	-$66.82M	-$51.01M	-$30.61M	-$21.85M	-$16.26M
EPS (Diluted)	n/a	-$3.16	-$2.90	-$5.08	-$3.80	-$2.67	-$2.66	-$2.77	n/a	n/a
Total Assets	$606.58M	$717.60M	$956.87M	$595.34M	$410.61M	$479.79M	$161.15M	$110.19M	$81.63M	n/a
Total Liabilities	$96.32M	$107.62M	$163.81M	$224.41M	$139.83M	$133.54M	$65.69M	$17.00M	$29.25M	n/a
Long-Term Debt	n/a	n/a	n/a	$30.70M	$30.32M	$29.87M	$14.51M	n/a	n/a	n/a
Shareholders' Equity	$510.25M	$609.98M	$793.06M	$370.93M	$270.78M	$346.25M	$95.46M	$93.20M	-$69.83M	-$47.18M
Cash & Equivalents	$510.05M	$628.11M	$879.52M	$526.42M	$339.15M	$438.68M	$0	$0	$0	n/a
Operating Cash Flow	-$206.05M	-$249.68M	-$164.72M	-$60.63M	-$86.11M	-$14.79M	-$17.79M	-$28.61M	-$26.08M	-$1.42M
Capital Expenditures	$2.23M	$2.35M	$1.24M	$2.93M	$18.99M	$2.03M	$1.20M	$1.55M	$1.19M	$1.11M
Free Cash Flow	-$208.28M	-$252.03M	-$165.96M	-$63.56M	-$105.10M	-$16.82M	-$18.99M	-$30.17M	-$27.26M	-$2.53M
Shares Outstanding	69.81M	69.37M	69.06M	42.43M	29.87M	29.58M	21.09M	17.99M	814.7K	n/a
Dividends Per Share	n/a	$0.00	$0.00	$0.00	$0.00	n/a	n/a	n/a	n/a	n/a
Weighted Average Diluted Shares	n/a	69.28M	58.21M	35.59M	29.66M	25.06M	19.15M	11.05M	n/a	n/a
EPS (Basic)	n/a	-$3.16	-$2.90	-$5.08	-$3.80	-$2.67	-$2.66	-$2.77	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView